🇺🇸 FDA
Patent

US 11261237

Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection

granted A61KA61K38/00A61K47/54

Quick answer

US patent 11261237 (Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection) held by BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA expires Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA
Grant date
Tue Mar 01 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K38/00, A61K47/54, A61K47/542, A61K47/55